Eight months ago, the U.S. Supreme Court interpreted the enablement requirement in the May 18, 2023, Amgen Inc. v. Sanofi decision.[1] Although the court did not change the law, affirming the U.S. Court of Appeals for the Federal Circuit's approach to enablement, its decision is one of the most impactful for patent enforcement, licensing and prosecution for decades to come across technologies.

Originally published in Law360.